Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome
OBJECTIVE-Dysregulated apolipoprotein (apo)C-III metabolism may account for hypertriglyceridemia and increased cardiovascular risk in the metabolic syndrome. This study investigated the dose-dependent effect of rosuvastatin on VLDL apoC-1II transport in men with the metabolic syndrome.RESEARCH DESIG...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
American Diabetes Association ADA
2008
|
| Online Access: | http://hdl.handle.net/20.500.11937/32130 |
| _version_ | 1848753575992229888 |
|---|---|
| author | Ooi, E. Watts, G. Chan, D. Chen, Meifania Nestel, P. Sviridov, D. Barrett, H. |
| author_facet | Ooi, E. Watts, G. Chan, D. Chen, Meifania Nestel, P. Sviridov, D. Barrett, H. |
| author_sort | Ooi, E. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | OBJECTIVE-Dysregulated apolipoprotein (apo)C-III metabolism may account for hypertriglyceridemia and increased cardiovascular risk in the metabolic syndrome. This study investigated the dose-dependent effect of rosuvastatin on VLDL apoC-1II transport in men with the metabolic syndrome.RESEARCH DESIGN AND METHODS-Twelve men with the metabolic syndrome were studied in arandomized double-blind crossover trial of 5-week intervention periods with placebo, 10 mg rosuvastatin,or 40 mg rosuvastatin, with 2-week placebo washouts between each period. VLDL apoC-IlI kinetics were examined using a stable isotope method and compartmental modeling at the end ofeachintervention period.RESULTS-Compared with placebo, there was a significant dose-dependent reduction with rosuvastatinin plasma triglyceride and VLDL apoC-III concentrations. Rosuvastatin significantly (P < 0.05) increasedVLDL apoC-I1I fractional catabolic rate (FCR) and decreased its production rate, with a significant (P <0.05) dose-related effect. With 40 mg rosuvastatin, changes in VLDL apoC-I1I concentration wereinversely associated with changes in VLDL apoC-IIl FCR and positively associated with VLDL apoC-1IIproduction rate (P < 0.05). Changes in VLDL apoC-1II concentration and production rate were positivelycorrelated with changes in VLDL apoS concentration and production rate and inversely correlated with VLDL apoB FCR (P < 0.05). Similar associations were observed with 10 mg rosuvastatin but were either less or not statistically significant.CONCLUSIONS-In this study, rosuvastatin decreased the production and increased the catabolism of VLDL apoC-IIl, a mechanism that accounted for the significant reduction in VLDL apoC-llI and triglyceride concentrations. This has implications for the management of cardiometabolic risk in obese subjects with the metabolic syndrome. |
| first_indexed | 2025-11-14T08:26:42Z |
| format | Journal Article |
| id | curtin-20.500.11937-32130 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T08:26:42Z |
| publishDate | 2008 |
| publisher | American Diabetes Association ADA |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-321302017-09-13T15:56:36Z Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome Ooi, E. Watts, G. Chan, D. Chen, Meifania Nestel, P. Sviridov, D. Barrett, H. OBJECTIVE-Dysregulated apolipoprotein (apo)C-III metabolism may account for hypertriglyceridemia and increased cardiovascular risk in the metabolic syndrome. This study investigated the dose-dependent effect of rosuvastatin on VLDL apoC-1II transport in men with the metabolic syndrome.RESEARCH DESIGN AND METHODS-Twelve men with the metabolic syndrome were studied in arandomized double-blind crossover trial of 5-week intervention periods with placebo, 10 mg rosuvastatin,or 40 mg rosuvastatin, with 2-week placebo washouts between each period. VLDL apoC-IlI kinetics were examined using a stable isotope method and compartmental modeling at the end ofeachintervention period.RESULTS-Compared with placebo, there was a significant dose-dependent reduction with rosuvastatinin plasma triglyceride and VLDL apoC-III concentrations. Rosuvastatin significantly (P < 0.05) increasedVLDL apoC-I1I fractional catabolic rate (FCR) and decreased its production rate, with a significant (P <0.05) dose-related effect. With 40 mg rosuvastatin, changes in VLDL apoC-I1I concentration wereinversely associated with changes in VLDL apoC-IIl FCR and positively associated with VLDL apoC-1IIproduction rate (P < 0.05). Changes in VLDL apoC-1II concentration and production rate were positivelycorrelated with changes in VLDL apoS concentration and production rate and inversely correlated with VLDL apoB FCR (P < 0.05). Similar associations were observed with 10 mg rosuvastatin but were either less or not statistically significant.CONCLUSIONS-In this study, rosuvastatin decreased the production and increased the catabolism of VLDL apoC-IIl, a mechanism that accounted for the significant reduction in VLDL apoC-llI and triglyceride concentrations. This has implications for the management of cardiometabolic risk in obese subjects with the metabolic syndrome. 2008 Journal Article http://hdl.handle.net/20.500.11937/32130 10.2337/dc08-0358 American Diabetes Association ADA fulltext |
| spellingShingle | Ooi, E. Watts, G. Chan, D. Chen, Meifania Nestel, P. Sviridov, D. Barrett, H. Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome |
| title | Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome |
| title_full | Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome |
| title_fullStr | Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome |
| title_full_unstemmed | Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome |
| title_short | Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome |
| title_sort | dose-dependent effect of rosuvastatin on vldl-apolipoprotein c-iii kinetics in the metabolic syndrome |
| url | http://hdl.handle.net/20.500.11937/32130 |